SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Thoratec

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess
of $100,000 From Investment in Thoratec Corporation to Contact Brower Piven
Before the March 25, 2014 Lead Plaintiff Deadline -- THOR

STEVENSON, Md., Jan. 31, 2014 (GLOBE NEWSWIRE) -- Brower Piven, A Professional
Corporation announces that a class action lawsuit has been commenced in the
United States District Court for the Northern District of California on behalf
of purchasers of Thoratec Corporation ("Thoratec" or the "Company")
(Nasdaq:THOR) securities during the period between April 29, 2010 and November
27, 2013, inclusive (the "Class Period").

If you have suffered a net loss from investment in Thoratec Corporation
securities purchased on or after April 29, 2010 and held through the
revelation of negative information on November 27, 2013, as described below,
you may obtain additional information about this lawsuit and your ability to
become a lead plaintiff, at no cost to you, by contacting Brower Piven at, by email at, by calling
410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley
Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined
experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action. Members of the Class will
be represented by the lead plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class, you must apply
to be appointed lead plaintiff no later than March 25, 2014 and be selected by
the Court. The lead plaintiff will direct the litigation and participate in
important decisions including whether to accept a settlement and how much of a
settlement to accept for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from investment in
Company units during the Class Period.

The complaint accuses the defendants of violations of the Securities Exchange
Act of 1934 by virtue of the defendants' failure to disclose during the Class
Period that its HeartMate II Left Ventricular Assist Device held significant
risk of pump thrombosis, causing numerous fatalities. According to the
complaint, following an April 4, 2012 recall issued on the Company's HeartMate
II heart pumps over concern for a potentially deadly defect and the November
27, 2013 release of a study in The New England Journal of Medicine that the
rate of pump thrombosis related to the use of the HeartMate II has been
increasing and is associated with substantial morbidity and mortality, the
value of Thoratec shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial
obligation or cost to you, or you may retain other counsel of your choice. You
need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven
         Brower Piven, A Professional Corporation
         Stevenson, Maryland
Press spacebar to pause and continue. Press esc to stop.